Scilex (NASDAQ:SCLX) Earns “Hold” Rating from D. Boral Capital

Scilex (NASDAQ:SCLX)‘s stock had its “hold” rating restated by investment analysts at D. Boral Capital in a research note issued on Friday,Benzinga reports.

Scilex Price Performance

Shares of SCLX traded down $0.06 during mid-day trading on Friday, hitting $0.19. The company’s stock had a trading volume of 2,050,416 shares, compared to its average volume of 1,440,097. Scilex has a fifty-two week low of $0.19 and a fifty-two week high of $2.30. The stock has a market capitalization of $46.96 million, a price-to-earnings ratio of -0.23 and a beta of 1.04. The firm has a 50-day moving average price of $0.30 and a 200 day moving average price of $0.53.

Scilex (NASDAQ:SCLX) last posted its quarterly earnings results on Friday, January 17th. The company reported ($0.18) earnings per share (EPS) for the quarter. As a group, equities analysts anticipate that Scilex will post -0.57 EPS for the current fiscal year.

Institutional Trading of Scilex

Several institutional investors and hedge funds have recently bought and sold shares of SCLX. Janus Henderson Group PLC raised its holdings in shares of Scilex by 28.7% during the fourth quarter. Janus Henderson Group PLC now owns 687,547 shares of the company’s stock valued at $293,000 after acquiring an additional 153,245 shares during the period. RA Capital Management L.P. raised its stake in Scilex by 296.7% during the 4th quarter. RA Capital Management L.P. now owns 1,036,218 shares of the company’s stock valued at $442,000 after purchasing an additional 775,039 shares during the period. Jane Street Group LLC lifted its holdings in shares of Scilex by 965.8% in the fourth quarter. Jane Street Group LLC now owns 321,480 shares of the company’s stock valued at $137,000 after purchasing an additional 291,316 shares in the last quarter. Northern Trust Corp boosted its position in shares of Scilex by 64.0% in the fourth quarter. Northern Trust Corp now owns 1,273,968 shares of the company’s stock worth $543,000 after buying an additional 497,182 shares during the period. Finally, Norges Bank purchased a new position in shares of Scilex during the fourth quarter valued at $204,000. Institutional investors and hedge funds own 69.67% of the company’s stock.

About Scilex

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.